Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use
Nearly 150,000 PCIs were performed on AMI patients in 2008
According to Millennium Research Group’s (MRG’s) US Markets for Interventional Cardiology Devices 2009 report, the use of drug-eluting stents will continue to climb steadily through 2013, driven in large part by the adoption of primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) patients, who accounted for nearly 150,000 PCIs in the U.S. in 2008.
In the past, primary PCI — defined as a PCI performed within 24 hours of the onset of symptoms — was mostly limited to facilities that had surgical back-up present. Studies have shown, however, that AMI patients who undergo primary PCI have improved outcomes over thrombolytics, even without surgical back up. Experts are now trying to reduce the time it takes to get patients to a cath lab — in some cases bypassing the emergency room — which will drive primary PCI adoption and support DES use in AMI patients.
Furthermore, a number of clinical trials in 2007 and 2008 released positive clinical data, which showed that ST-elevation myocardial infarction (STEMI) patients who receive aspiration with stenting have better blood flow, enhanced myocardial function, and lower mortality rates than patients who received angioplasty with stenting or direct stenting.
“The TAPAS trial indicated that STEMI patients treated with aspiration prior to stenting had over 30% lower mortality in the following year compared to those who had angioplasty-with-stent procedures,” says Stephanie LaBelle, Senior Analyst at MRG. “As a result, the portion of primary PCIs using aspiration rather than predilation prior to stenting will grow in AMI patients through 2013.”
MRG’s US Markets for Interventional Cardiology Devices 2009 report provides coverage of key industry trends, including new segments on the treatment of AMI patients and bifurcated lesions, as well as the launch of new devices from Abbott Vascular, Boston Scientific, and Medtronic. Additional leading competitors covered include AngioScore, Cordis, C.R. Bard, Cook Medical, ev3, St. Jude Medical, Terumo Medical, and many more.